Bulking Agents for the Treatment of Stress Urinary Incontinence in Females

Contura

Status

Completed

Conditions

Stress Urinary Incontinence

Treatments

Device: Bulkamid

Device: Contigen

Study type

Interventional

Funder types

Industry

Other

Identifiers

NCT00629083

CONSUI-US01

Details and patient eligibility

About

The primary purpose of this study is to demonstrate the safety and effectiveness of Bulkamid® in the treatment of stress urinary incontinence (SUI) due to intrinsic sphincter deficiency (ISD) in adult women who have SUI or stress predominant mixed incontinence

Full description

The study is a single-masked, randomized, comparative multi-center, 2-arm parallel study intended to demonstrate the safety and effectiveness of Bulkamid® vs. Contigen® for the treatment of stress urinary incontinence (SUI)due to intrinsic sphincter deficiency (ISD) in adult women who have SUI or stress predominant mixed incontinence.

Subjects will be randomized to receive either a polyacrylamide hydrogel (Bulkamid®) treatment, or a collagen treatment (Contigen®) using a 2:1 ratio and will be masked to the treatment. Screening baseline evaluations and collagen skin testing will be completed to determine eligible subjects. Following a negative skin test, a subject will be randomized and treated with Bulkamid® or the comparator device at the Treatment Visit.

Subjects that are not continent will be considered for re-injection. A maximum of 3 injections (initial + 2 re-injections) are allowed. After the last injection, subjects will attend the 3-Month, 6-Month and 12-Month Follow-up Visits plus a telephone contact at 9 months.

The study will record objective incontinence measurements, subject's perception of effectiveness and quality of life assessments. Adverse events will be recorded throughout the study.

Each subject will be followed for 12 months from the last injection.

Enrollment

345 patients

Sex

Female

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Be female 18 or more years of age.
Females of childbearing potential or <2 years post-menopausal must be using 2 forms of contraception.
Suffer from SUI for at least 6 months.
Have failed 2 previous non-invasive therapies for 3 months each.
Have at least 3 incontinence episodes measured over 3 days.
Have a baseline 24h pad test weight greater than or equal to 5 gm.
Have VLPP ≤ 100 cm H2O.
Have maximum cystometric capacity equal or higher than (≥) 250 mL.
Have PVR urine ≤ 100 mL.
Have a life expectancy of more than 2 years.

Exclusion criteria

Has urethral hypermobility >30 deg.
Has predominant urge incontinence.
Has detrusor overactivity.
Regularly or intermittently users of urethral catheter.
Has had previous radiation treatment in the pelvic floor.
Has had previous urethral surgery (i.e. fistula, diverticula)or urethral bulking. Failed sling or colposuspension procedure for at least 6 months may be included.
Suffers from known polyuria.
Has had three (3) or more culture-proven bacterial UTIs in the last 12 months.
Has a current infection (urethritis, cystitis or vaginitis).
Has unevaluated hematuria.
Has a Prolapse Stage greater than II.
Has a BMI>35 kg/m2.
Is taking pharmacological treatment for stress urinary incontinence, 4 weeks prior to screening.
Is allergic to bovine collagen.
Is known to suffer from severe allergies or anaphylaxis.
Suffers from autoimmune diseases (e.e. connective tissue diseases) that could confound the treatment.
Is currently taking or has taken systemic corticosteroids within the past 3 months.
Currently has cancer or has a history of any cancer within the past 5 years (skin cancer with no evidence of skin malignancy, for at least 2 years, can be included).
Currently suffering from unstable cardiovascular disease, cancer or uncontrolled diabetes.
Has active herpes genitalis.
Is currently participating in any other clinical trial or has participated in another clinical trial within 3 months of screening/baseline visit.
Is pregnant, lactating or intending to become pregnant.
Is not physically able to perform study procedure.
Has a neurogenic bladder
Had a vaginal delivery within 3 months prior to screening.